HC Wainwright Reiterates Buy Rating for Krystal Biotech (NASDAQ:KRYS)

HC Wainwright reissued their buy rating on shares of Krystal Biotech (NASDAQ:KRYS - Free Report) in a report published on Tuesday,Benzinga reports. The firm currently has a $240.00 target price on the stock. HC Wainwright also issued estimates for Krystal Biotech's Q2 2025 earnings at $1.71 EPS, Q3 2025 earnings at $1.94 EPS and Q4 2025 earnings at $2.55 EPS.

KRYS has been the topic of several other reports. Chardan Capital upped their price target on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a "buy" rating in a report on Thursday, February 20th. Citigroup increased their target price on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a "neutral" rating in a research note on Thursday, February 20th. Cantor Fitzgerald restated an "overweight" rating and issued a $215.00 target price on shares of Krystal Biotech in a research note on Thursday, February 20th. Finally, Jefferies Financial Group began coverage on Krystal Biotech in a report on Wednesday, March 5th. They set a "buy" rating and a $245.00 target price on the stock. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $218.63.

Krystal Biotech Stock Down 3.6 %

NASDAQ KRYS traded down $4.94 during mid-day trading on Tuesday, hitting $132.23. The stock had a trading volume of 329,798 shares, compared to its average volume of 300,407. Krystal Biotech has a 52-week low of $131.71 and a 52-week high of $219.34. The company has a market cap of $3.82 billion, a price-to-earnings ratio of 44.22 and a beta of 0.79. The company has a 50 day simple moving average of $171.56 and a 200 day simple moving average of $170.04.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported $1.20 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.38 by ($0.18). The company had revenue of $88.18 million during the quarter, compared to analysts' expectations of $98.66 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. As a group, equities analysts anticipate that Krystal Biotech will post 6.14 earnings per share for the current fiscal year.

Insider Activity

In other Krystal Biotech news, CAO Kathryn Romano sold 750 shares of the company's stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $175.22, for a total value of $131,415.00. Following the transaction, the chief accounting officer now directly owns 12,604 shares in the company, valued at $2,208,472.88. This represents a 5.62 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the completion of the transaction, the insider now directly owns 1,463,711 shares of the company's stock, valued at approximately $260,233,178.69. This represents a 1.68 % decrease in their position. The disclosure for this sale can be found here. Insiders own 13.70% of the company's stock.

Hedge Funds Weigh In On Krystal Biotech

Large investors have recently added to or reduced their stakes in the business. Norges Bank purchased a new position in shares of Krystal Biotech in the fourth quarter worth about $34,391,000. Soleus Capital Management L.P. increased its stake in Krystal Biotech by 65.2% in the 4th quarter. Soleus Capital Management L.P. now owns 358,379 shares of the company's stock worth $56,144,000 after purchasing an additional 141,400 shares during the period. GAMMA Investing LLC lifted its position in Krystal Biotech by 50,249.4% in the first quarter. GAMMA Investing LLC now owns 121,342 shares of the company's stock valued at $21,878,000 after purchasing an additional 121,101 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Krystal Biotech during the fourth quarter valued at approximately $15,989,000. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of Krystal Biotech by 16.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 509,459 shares of the company's stock worth $79,812,000 after purchasing an additional 71,200 shares during the last quarter. Hedge funds and other institutional investors own 86.29% of the company's stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).